Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study

被引：3
|
作者：
Di Bona, Danilo [1 ]
Nettis, Eustachio [1 ]
Minenna, Elena [2 ]
Lovecchio, Antonella [1 ]
Paolino, Donato [1 ]
Cristina Nizi, Maria [3 ]
Albanesi, Marcello [1 ]
Ridolo, Erminia [3 ]
Filomena Caiaffa, Maria [2 ]
Macchia, Luigi [1 ]
机构：
[1] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Sch & Chair Allergol & Clin Immunol, Piazza Giulio Cesare 11, I-70124 Bari, Italy
[2] Univ Foggia, Dept Med & Surg Sci, Foggia, Italy
[3] Univ Parma, Med & Surg Dept, Allergy & Clin Immunol, Parma, Italy
来源：
ALLERGY | 2020年 / 75卷 / 10期
关键词：
URTICARIA;
D O I：
10.1111/all.14341
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2681 / 2684
页数：4
相关论文
共 50 条
  • [1] Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation
    Bras, Rita
    Costa, Celia
    Limao, Rita
    Caldeira, Leonor Esteves
    Paulino, Marisa
    Pedro, Elisa
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (08): : 2392 - 2402
  • [2] Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study
    Deschildre, Antoine
    Roussel, Juliette
    Drumez, Elodie
    Abou-Taam, Rola
    Rames, Cinthia
    Le Roux, Pascal
    Pouessel, Guillaume
    Scalbert, Manuela
    Bonnel, Cecile
    Mitha, Sarah
    Boileau, Sophie
    Mordacq, Clemence
    Thumerelle, Caroline
    Labreuche, Julien
    Lejeune, Stephanie
    Marguet, Christophe
    ALLERGY, 2019, 74 (05) : 999 - 1003
  • [3] Adherence to omalizumab: a real-life study
    Campisi, Raffaele
    Crimi, Claudia
    Noto, Alberto
    Foschino, Maria Pia
    Valenti, Giuseppe
    Viviano, Vittorio
    Pelaia, Corrado
    Ricciardi, Luisa
    Scichilone, Nicola
    Crimi, Nunzio
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [4] Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
    Galluzzo, Marco
    Talamonti, Marina
    Atzori, Laura
    Bardazzi, Federico
    Campanati, Anna
    Di Cesare, Antonella
    Diotallevi, Federico
    Flori, Maria Laura
    Mugheddu, Cristina
    Offidani, Annamaria
    Piaserico, Stefano
    Russo, Filomena
    Sacchelli, Lidia
    Bianchi, Luca
    Prignano, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (04) : 547 - 554
  • [5] Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study
    Pieragostini, Remi
    Xhaard, Alienor
    Sauvageon, Helene
    Madelaine, Isabelle
    Touratier, Sophie
    Denis, Blandine
    MEDICAL MYCOLOGY, 2023, 61 (04)
  • [6] Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study
    de Llano, Luis Perez
    Zubeldia, Jose Manuel
    Herraez, Lys
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [7] Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study
    Shah-Hosseini, Kija
    Krudewig, Eva-Maria
    Hadler, Meike
    Karagiannis, Efstrathios
    Moesges, Ralph
    ADVANCES IN THERAPY, 2017, 34 (06) : 1382 - 1397
  • [8] Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study
    Kija Shah-Hosseini
    Eva-Maria Krudewig
    Meike Hadler
    Efstrathios Karagiannis
    Ralph Mösges
    Advances in Therapy, 2017, 34 : 1382 - 1397
  • [9] Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study
    Dominique Simon
    Bruno Detournay
    Evelyne Eschwege
    Stephane Bouée
    Jacques Bringer
    Claude Attali
    Sylvie Dejager
    Diabetes Therapy, 2014, 5 : 207 - 224
  • [10] Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study
    Simon, Dominique
    Detournay, Bruno
    Eschwege, Evelyne
    Bouee, Stephane
    Bringer, Jacques
    Attali, Claude
    Dejager, Sylvie
    DIABETES THERAPY, 2014, 5 (01) : 207 - 224
12345